KRAS and colorectal carcinoma: In contrast to the limited efficacy of KRAS G12C inhibitor monotherapy for KRAS G12C mutated advanced CRC, the combination of RTK and KRAS G12C inhibitors has shown promising efficacy with reasonable safety.